NEWS

Chinese biotech stock is reportedly “booming” while outperforming its U.S. counterpart, delivering the latest data point in a worrisome trend for America’s patients, economy, and national security.   According to a recent STAT article , while U.S. biotech stock is up 20% this year, China's is up a whopping 80%. At first glance, this could be dismissed as another short-term spike. Similar ones were observed between 2018 and 2021 when a flurry of Chinese drugmakers launched IPO

North Carolina’s life sciences industry is a hub of innovation that drives economic growth and advances health care.   Its research and biotech sectors employ more than 226,000 people  and contribute more than $80 billion  to the state’s economy. Through thousands of clinical trials involving millions of participants, the state plays a central role in finding discoveries that improve patient care nationwide.   That’s where strong intellectual property (IP) protections come in

The urgency for the U.S. to maintain its leadership in biotechnology – especially in competition with China – is growing. This issue came into sharp focus during recent discussions between lawmakers and industry experts at a Senate HELP Committee hearing .    “I recently spoke to a group of biotech leaders,” Sen. Bill Cassidy (R-LA) said. “They, in varying degrees, view China as a collaborator, a competitor and as a threat. When developers are looking outside our country for

As we wrap up IP Month, WWFH Executive Director Dan Leonard sat down for a conversation with David Kappos of the Council for Innovation Promotion. As former Under Secretary of Commerce and Director of the U.S. Patent and Trademark Office and Vice President and Chief Intellectual Property Lawyer at IBM, Kappos is an expert in the innovation and intellectual property (IP) space.  Throughout the conversation, Kappos underscores the fundamental importance of strong IP protections

During October’s Intellectual Property Month, WWFH’s Executive Director Dan Leonard sat down with Laura Schoppe of Tech Pipeline  for a timely conversation about the future of American innovation. With China's biopharmaceutical sector gaining ground and policy challenges mounting at home, Laura's insights come at a critical moment. Drawing on her experience in academic technology transfer and biopharmaceutical innovation, Laura offers a nuanced look at both the opportunities

In recognition of Intellectual Property (IP) Month, We Work For Health 's Executive Director Dan Leonard sat down with Stephen Ezell of the Information Technology and Innovation Foundation (ITIF) to explore the state of America’s innovation ecosystem. Their conversation covered pressing topics such as rising competitive challenges from China and how misguided policy choices could impact the U.S.’s global standing for generations. Ezell, who directs ITIF’s Center for Life Sci

Last week, the Senate Judiciary Committee’s Subcommittee on Intellectual Property held a hearing on the Patent Eligibility Restoration Act  (PERA) , which would bring much-needed clarity to the patent system that is essential for the United States maintaining its global leadership in the life sciences.   October is Intellectual Property Month, and We Work For Health is continuing to call on policymakers to prioritize meaningful reforms and modernize the intellectual property

A Hong Kong-based healthcare expert recently warned that China's biotechnology sector has achieved such rapid advancement and cost advantages that it may fundamentally reshape the global pharmaceutical landscape and potentially displace the United States as the world’s innovator of new cures. Cui Cui, managing director and head of Asia healthcare research at Jefferies, recently spoke to Endpoints News about the dramatic transformation of China’s life sciences sector and the

There is yet another metric depicting how China is aggressively readying itself to challenge, and potentially surpass,...

America's biopharmaceutical sector is delivering unprecedented investment in domestic innovation and manufacturing capacity. In 2025...

Former FDA commissioner Scott Gottlieb recently appeared on an Endpoints News video series to share insight  into China's rapid ascent in...

China’s life science footprint once functioned as little more than a factory on the global stage. It supplied high-volume generics and...